PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424467
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1424467
The rapid medical diagnostic kits market size is expected to reach US$ 40.3 billion by 2030, from US$ 21.6 billion in 2023, at a CAGR of 9.3% during the forecast period.
Rapid diagnostic tests (RDTs) refer to a group of diagnostics categorized by performance characteristics rather than the specific analyte or test platform. Such assays have relatively short performance times, provide results to inform clinical decision making, and enable management at the point-of-care (POC). RDTs are available in a variety of test formats and platforms for various detection targets. RDTs are designed for detecting pathogen-specific antigens or nucleic acid sequences, as well as host antibody responses against certain pathogens.
Increasing research and development activities by the market players to develop novel product for the rapid diagnosis of infectious diseases. Moreover, the increasing prevalence of infectious diseases globally is expected to drive market growth over the forecast period. For instance, according to the data published by the Center for Disease Control and Prevention in 2019, the number of new tuberculosis cases was 8,916, and the number of new Lyme disease cases was 34,945.
Rapid Medical Diagnostic Kits Market Segmentation: